Metagenomi Therapeutics, Inc. Increase (Decrease) in Accounts Payable
Metagenomi Therapeutics, Inc. (MGX) reported Increase (Decrease) in Accounts Payable of $1.11 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-10
- Metagenomi Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $319.00K, a 331.08% increase year-over-year.
- Metagenomi Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $795.00K, a 64.03% decline year-over-year.
- Metagenomi Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $346.00K.
- Metagenomi Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$1.58M.
- Metagenomi Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was $1.05M.
- Metagenomi Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$1.11M.
- Metagenomi Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$84.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $319.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.11M 10-Q · filed 2026-08-10 | $1.46M derived: sum of 3 quarters · filed 2026-08-10 | -$116.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $795.00K 10-Q · filed 2026-05-11 | $1.14M derived: sum of 2 quarters · filed 2026-05-11 | -$435.00K derived: sum of 3 quarters · filed 2026-05-11 | -$361.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $346.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$1.23M derived: sum of 2 quarters · filed 2026-03-05 | -$1.16M derived: sum of 3 quarters · filed 2026-08-10 | $1.05M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.50M derived: sum of 2 quarters · filed 2026-08-10 | $708.00K 10-Q · filed 2025-11-12 | -$1.86M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $74.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $2.28M 10-Q · filed 2026-08-10 | -$286.00K derived: sum of 3 quarters · filed 2026-08-10 | -$556.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $2.21M 10-Q · filed 2026-05-11 | -$360.00K derived: sum of 2 quarters · filed 2026-05-11 | -$630.00K derived: sum of 3 quarters · filed 2026-05-11 | -$2.06M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$2.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$2.84M derived: sum of 2 quarters · filed 2026-03-05 | -$4.26M derived: sum of 3 quarters · filed 2026-03-05 | -$1.11M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$270.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.70M derived: sum of 2 quarters · filed 2025-11-12 | $1.46M 10-Q · filed 2025-11-12 | -$1.06M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.73M 10-Q · filed 2025-08-12 | -$789.00K derived: sum of 3 quarters · filed 2025-08-12 | $768.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $3.16M 10-Q · filed 2025-05-13 | $636.00K derived: sum of 2 quarters · filed 2025-05-13 | $2.19M derived: sum of 3 quarters · filed 2025-05-13 | $1.87M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$966.00K derived: sum of 2 quarters · filed 2025-03-17 | -$1.29M derived: sum of 3 quarters · filed 2025-03-17 | -$84.00K 10-K · filed 2025-03-17 |
| 2023-09-30 | $1.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.23M derived: sum of 2 quarters · filed 2024-11-13 | $2.44M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$323.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $882.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $1.21M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |